Inspire Medical Systems Inc
NYSE:INSP
Inspire Medical Systems Inc
Inspire Medical Systems Inc. emerged as a beacon of innovation in the medical technology landscape, carving a niche within the realm of obstructive sleep apnea (OSA) treatment. Founded with a vision to redefine the approach to sleep disorders, the company developed a breakthrough solution—a device that stimulates the hypoglossal nerve to maintain an open airway during sleep. This technology, known as Inspire therapy, represents a significant departure from traditional treatments like the cumbersome and often uncomfortable Continuous Positive Airway Pressure (CPAP) machines. By addressing the root cause of airway obstruction, Inspire provides an effective, less intrusive alternative, enhancing the overall quality of life for patients who struggle with conventional methods.
Inspire Medical Systems makes money by marketing its implantable device primarily through a network of sleep centers and hospitals. The company operates in a business model that combines device sales with a supportive service infrastructure, ensuring that both healthcare providers and patients are well-acquainted with its innovative therapy. The revenue stream is fueled not only by the initial sales of the device but also through ongoing follow-ups and software updates necessary for optimal device functionality. By positioning itself at the intersection of customer care and cutting-edge technology, Inspire captures significant value in the growing OSA market, all while reinforcing its reputation as a leader in innovative medical solutions.
Inspire Medical Systems Inc. emerged as a beacon of innovation in the medical technology landscape, carving a niche within the realm of obstructive sleep apnea (OSA) treatment. Founded with a vision to redefine the approach to sleep disorders, the company developed a breakthrough solution—a device that stimulates the hypoglossal nerve to maintain an open airway during sleep. This technology, known as Inspire therapy, represents a significant departure from traditional treatments like the cumbersome and often uncomfortable Continuous Positive Airway Pressure (CPAP) machines. By addressing the root cause of airway obstruction, Inspire provides an effective, less intrusive alternative, enhancing the overall quality of life for patients who struggle with conventional methods.
Inspire Medical Systems makes money by marketing its implantable device primarily through a network of sleep centers and hospitals. The company operates in a business model that combines device sales with a supportive service infrastructure, ensuring that both healthcare providers and patients are well-acquainted with its innovative therapy. The revenue stream is fueled not only by the initial sales of the device but also through ongoing follow-ups and software updates necessary for optimal device functionality. By positioning itself at the intersection of customer care and cutting-edge technology, Inspire captures significant value in the growing OSA market, all while reinforcing its reputation as a leader in innovative medical solutions.
Revenue Growth: Inspire Medical reported fourth quarter revenue of $269 million (up 12%) and full year revenue of $912 million (up 14%), driven by growth at existing and new centers.
Reimbursement Uncertainty: The company faces significant reimbursement headwinds due to a transition to CPT code 64582 with a -52 modifier for Inspire V procedures, with expected physician fee reductions between 10% and 50%.
2026 Guidance: Revenue guidance for 2026 was revised and widened to $950 million to $1 billion, reflecting 4% to 10% growth and accounting for the range of possible reimbursement impacts.
Profitability: Fourth quarter net income per diluted share rose to $4.66, and operating margin improved due to sales leverage and higher Inspire V mix. The company ended 2025 with $405 million in cash and investments.
First Quarter Outlook: Q1 2026 revenue is expected to be flat year-over-year, with a projected net loss due to coding uncertainty and higher operating expenses.
Operational Adjustments: Inspire is consolidating sales territories, increasing field clinical reps, and maintaining cost discipline to adapt to the reimbursement environment.
New Product & Regulatory: Inspire V has shown superior clinical performance vs. Inspire IV and recently received FDA approval for 3 Tesla MRI compatibility. Longer-term, the company is seeking a dedicated CPT code for Inspire V.
Market & Demand: Patient demand remains strong, with increased marketing and over 90% of centers now implanting Inspire V. The WISeR Medicare prior authorization program is impacting procedures in six states in Q1.
